Patents by Inventor Guadalupe Guzman
Guadalupe Guzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10357103Abstract: A height-adjustable desk has a base, having a support, a middle portion of a rear side of the support having a column disposed thereon and being upright, a front side of the column having a plurality of slots, the slots being spaced along the column. The desk has a shelf, having a frame, an upper desk top and a lower desk top, the frame disposed on and moveably surrounding the column, the frame having an insert corresponding to the slots, the insert configured to be inserted into one of the slots, the upper desk top located at the frame, the lower desk top located at the frame lower than the upper desk top.Type: GrantFiled: February 7, 2018Date of Patent: July 23, 2019Inventor: Guadalupe Guzman
-
Publication number: 20180228279Abstract: A height-adjustable desk has a base, having a support, a middle portion of a rear side of the support having a column disposed thereon and being upright, a front side of the column having a plurality of slots, the slots being spaced along the column. The desk has a shelf, having a frame, an upper desk top and a lower desk top, the frame disposed on and moveably surrounding the column, the frame having an insert corresponding to the slots, the insert configured to be inserted into one of the slots, the upper desk top located at the frame, the lower desk top located at the frame lower than the upper desk top.Type: ApplicationFiled: February 7, 2018Publication date: August 16, 2018Inventor: Guadalupe Guzman
-
Patent number: 9463235Abstract: Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.Type: GrantFiled: December 16, 2013Date of Patent: October 11, 2016Assignee: CENTRO DE INGENIERÍA GENEÉTICA Y BIOTECHNOLOGÍAInventors: Lisset Hermida Cruz, Lázaro Gil González, Alienys Izquierdo Oliva, Ernesto Marcos López, Edith Suzarte Portal, Gerardo Enrique Guillén Nieto, María Guadalupe Guzmán Tirado, Iris Valdés Prado, Laura Lazo Vazquez, Angelica de la Caridad Garcia Arechavaleta, Mayling Alvarez Vera, Jorge Castro Velazco, Lázaro López Fernández, Rosa Liset Ramírez Bartutis, Yusleidi de la Caridad Pérez Fuentes, Olga Lidia Pérez Guevara, Yaremy Romero Fernández
-
Publication number: 20150328304Abstract: Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.Type: ApplicationFiled: December 16, 2013Publication date: November 19, 2015Inventors: Lisset Hermida Cruz, Lázaro Gil González, Alienys Izquierdo Oliva, Ernesto Marcos López, Edith Suzarte Portal, Gerardo Enrique Guillén Nieto, María Guadalupe Guzmán Tirado, Iris Valdés Prado, Laura Lazo Vazquez, Angelica de la Caridad García Arechavaleta, Mayling Alvarez Vera, Jorge Castro Velazco, Lázaro López Fernández, Rosa Liset Ramírez Bartutis, Yusleidi de la Caridad Pérez Fuentes, Olga Lidia Pérez Guevara, Yaremy Romero Fernández
-
Patent number: 8105606Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: April 26, 2011Date of Patent: January 31, 2012Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20110200628Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7947281Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: June 12, 2009Date of Patent: May 24, 2011Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Richardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7790173Abstract: This invention describes a pharmaceutical compound which has the capsid protein of Dengue virus and which is capable of inducing, in the receptor, a protective immune response before the viral challenge, without inducing the Ab-dependent enhancement phenomenon.Type: GrantFiled: September 18, 2006Date of Patent: September 7, 2010Assignee: Centro de Ingenieria Genetica Y BiotecnologiaInventors: Laura Lazo Vázquez, Lisset Hermida Cruz, Carlos López Abarrategui, Beatriz de la Caridad Sierra Vázquez, Susana Vázquez Ramundo, Iris Valdez Prado, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzmán Tirado, Aida Zulueta Morales
-
Publication number: 20090274718Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 12, 2009Publication date: November 5, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7566457Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonspecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: February 13, 2007Date of Patent: July 28, 2009Assignee: Centro de Ingeniera Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7279164Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: July 12, 2002Date of Patent: October 9, 2007Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20040234951Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 7, 2004Publication date: November 25, 2004Inventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 6383488Abstract: The present invention relates to five synthetic peptides of pre-M/M protein of Dengue-2 virus, corresponding to amino acid sequences 3-31, 45-67, 57-92, 69-93 and 103-124. The anti-peptide immune response was evaluated in mice. Recombinant fusion proteins were also obtained, including regions of pre-M/M protein. The presence of B cell epitopes in both mice and humans was demonstrated in the pre-M/M protein peptides. Peptides 3-31 and 103-124 elicited neutralizing antibodies against the four serotypes of Dengue virus. Virus-specific proliferative responses were demonstrated in mice immunized with non-conjugated peptides 3-31 and 57-92. Mice immunized with conjugated peptides 3-31, 57-92, and 69-93 were protected when they were challenged with Dengue-2 virus. Thus, the presence of sequential epitopes in Pre-M/M protein of Dengue-2 virus was demonstrated, as well as their relevance in the immune response against this flavivirus.Type: GrantFiled: October 14, 1999Date of Patent: May 7, 2002Assignees: Centro de Ingeniera Genetic Y Biotechnologies (CIGB), Instituto de Medicina Tropical “Pedro Kouri”Inventors: Susana Vazquez Ramudo, Guadalupe Guzman Tirado, Gerardo Enrique Guillen Nieto, Orlando Luis Pardo Lazo, Glay Chinea Santiago, Ana Beatriz Perez Diaz, Maritza Pupo Antunez, Rosmari Rodriguez Roche, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Gabriel Padron Palomares, Maylin Alvarez Vera, Luis Morier Diaz, Omaida Perez Insuita, Jose Luis Pelegrino Martinez De La Cotera
-
Patent number: D943314Type: GrantFiled: June 24, 2019Date of Patent: February 15, 2022Inventor: Guadalupe Guzman